Breaking

Gilead nears deal to buy Immunomedics for more than $20 bln -WSJ


(Reuters) – Gilead Sciences Inc <GILD.O> is nearing a deal to buy biopharmaceutical company Immunomedics Inc <IMMU.O> for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday.


A deal for Immunomedics, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer called Metastatic Triple-Negative Breast Cancer, could be announced Monday if not sooner, the Journal said https://www.wsj.com/articles/gilead-nears-deal-to-buy-immunomedics-for-more-than-20-billion-11599936777?mod=hp_lead_pos2, citing people familiar with the matter.


Discussions between Gilead and Immunomedics were initially centered around a partnership before shifting to a full-fledged takeover negotiation, the Journal added.


Gilead and Immunomedics did not respond immediately to emailed requests from Reuters for comment.


Shares of Immunomedics, which last month reported positive data from a late-stage confirmatory study for Trodelvy, have nearly doubled this year, giving the company a valuation of close to $10 billion.


An acquisition of Immunomedics would add to several deals Gilead inked this year with the aim of expanding its oncology portfolio.


It bought a 49.9% stake in cancer drug developer Pionyr Immunotherapeutics in June for $275 million, just months after paying $4.9 billion for Forty Seven Inc, maker of an experimental treatment that targets blood cancer.


(Reporting by Ismail Shakil in Bengaluru; Editing by Chizu Nomiyama)


No comments:

Post a Comment

Technology